Lyell Immunopharma Inc (LYEL)
2.10
-0.07
(-3.23%)
USD |
NASDAQ |
Jun 18, 16:00
2.095
0.00 (0.00%)
After-Hours: 20:00
Lyell Immunopharma Cash and Short Term Investments (Quarterly): 526.30M for March 31, 2024
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 526.30M |
| December 31, 2023 | 546.22M |
| September 30, 2023 | 575.43M |
| June 30, 2023 | 595.75M |
| March 31, 2023 | 612.77M |
| December 31, 2022 | 640.15M |
| September 30, 2022 | 648.13M |
| Date | Value |
|---|---|
| June 30, 2022 | 655.56M |
| March 31, 2022 | 613.91M |
| December 31, 2021 | 614.79M |
| September 30, 2021 | 618.92M |
| June 30, 2021 | 824.52M |
| March 31, 2021 | 604.93M |
| December 31, 2020 | 612.62M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
526.30M
Minimum
Mar 2024
824.52M
Maximum
Jun 2021
620.72M
Average
613.34M
Median
Cash and Short Term Investments (Quarterly) Benchmarks
| GlycoMimetics Inc | 31.28M |
| Candel Therapeutics Inc | 25.71M |
| Eliem Therapeutics Inc | 105.03M |
| Entrada Therapeutics Inc | 327.41M |
| NovaBay Pharmaceuticals Inc | 1.823M |